Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Lung Cancer

Clinical Trial at: Compass Oncology - Vancouver

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: Lung Cancer
USOR Number: 19020

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Portland

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: Lung Cancer
USOR Number: 19020

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Portland

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: Lung Cancer
USOR Number: 19020

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Tigard

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

  • Details

ClinicalTrials.gov ID: NCT03906071
Diagnosis Type: Lung Cancer
USOR Number: 19018

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Vancouver

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

  • Details

ClinicalTrials.gov ID: NCT03906071
Diagnosis Type: Lung Cancer
USOR Number: 19018

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Portland

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

  • Details

ClinicalTrials.gov ID: NCT03906071
Diagnosis Type: Lung Cancer
USOR Number: 19018

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Lung Cancer

Clinical Trial at: Compass Oncology - Portland

516-005: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

  • Details

ClinicalTrials.gov ID: NCT03906071
Diagnosis Type: Lung Cancer
USOR Number: 19018

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

More Details View Practice Page

Lymphomas

Clinical Trial at: Compass Oncology - Vancouver

A Phase Ib, open-label, randomized study to assess safety and preliminary efficacy of Tafasitamab in addition to R-CHOP or Tafasitamab plus Lenalidomide in addition to R-CHOP in patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) � First-MIND (MOR208C107)

  • Details

ClinicalTrials.gov ID: NCT04134936
Diagnosis Type: Lymphomas
USOR Number: 19015

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Ovarian Cancer

Clinical Trial at: Compass Oncology - Tigard

ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

  • Details

ClinicalTrials.gov ID: NCT03940196
Diagnosis Type: Ovarian Cancer
USOR Number: 18269

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708-7600

More Details View Practice Page

Ovarian Cancer

Clinical Trial at: Compass Oncology - Vancouver

ENGOT-ov50 / INNOVATE-3: Pivotal, Randomized, Open-Label Study ofTumor Treating Fields (TTFields, 200kHz) Concomitant with WeeklyPaclitaxel for the Treatment of Recurrent Ovarian Cancer

  • Details

ClinicalTrials.gov ID: NCT03940196
Diagnosis Type: Ovarian Cancer
USOR Number: 18269

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page
1 … 3 4 5 6 7 … 12

Find a Location

With more than 2,500 physicians and over 600 treatment locations across the country, the advanced cancer care you need may be available right in your local community from a practice in The US Oncology Network. Search to see if there is a center near you.